

MECHANISTIC INSIGHT INTO MEDICINAL PROPERTIES OF INDONESIAN DIVERSE MANGROVE SPECIES: A REVIEW

MUHTADI MUHTADI^{1*}, DWI B. PAMBUDI^{1,2}, MARYATI MARYATI¹

¹Doctoral Program, Faculty of Pharmacy, Universitas Muhammadiyah Surakarta, Indonesia. ²Faculty of Health Sciences, Universitas Muhammadiyah Pekajangan Pekalongan, Indonesia

*Corresponding author: Muhtadi Muhtadi; *Email: muhtadi@ums.ac.id

Received: 06 May 2024, Revised and Accepted: 27 Aug 2024

ABSTRACT

Mangrove ecosystems in Indonesia harbor a rich diversity of plant species, some of which have been traditionally recognized for their medicinal properties. This study aims to provide mechanistic insights into the medicinal potential of various mangrove species found in Indonesian coastal regions. Through a comprehensive analysis of pharmacological activities and underlying mechanisms, our research seeks to elucidate the therapeutic properties of these diverse mangrove plants. The key terms "Mangrove", "Pharmacological", and "Indonesia" used for searching in three online databases: Science Direct, PubMed, and Google Scholar. The investigation into the pharmacological properties of mangrove species revealed versatile mechanisms of action. Notably, a convergence is observed in their antioxidant mechanisms, as exemplified by *Aegiceras corniculatum*, *Avicennia marina*, and *Rhizophora mucronata*, showcasing robust effects in DPPH, ABTS, and FRAP assays. Additionally, the study highlights significant findings in the realm of anti-inflammatory activities. Mangrove species like *Aegialitis rotundifolia*, *Ceriops decandra*, and *Rhizophora apiculata* demonstrate notable anti-inflammatory effects by inhibiting enzymes like LOX and responding positively to carrageenan induction. A commonality is unveiled in antibacterial effects, with species like *Avicennia marina*, *Ceriops tagal*, and *Excoecaria agallocha* exhibiting potent antibacterial properties in agar diffusion assays. These findings underscore the potential of mangrove species in combating microbial infections through distinct antibacterial mechanisms. Furthermore, understanding the mechanisms behind the medicinal properties of Indonesian mangrove species is crucial for both conservation efforts and the development of novel pharmaceuticals.

Keywords: Mangrove ecosystems, Pharmacological, Diversity, Mangrove species

© 2024 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>). DOI: <https://dx.doi.org/10.22159/ijap.2024.v16s5.52488> Journal homepage: <https://innovareacademics.in/journals/index.php/ijap>

INTRODUCTION

Mangrove ecosystems, characterized by a unique interface between terrestrial and marine environments, are renowned reservoirs of biodiversity with ecological and economic significance [1]. Within the Indonesian archipelago, diverse mangrove species thrive along the coastal zones, offering a plethora of ecological services. Beyond their ecological roles, these mangroves have been integral to traditional medicine practices, drawing attention to their potential medicinal properties [2]. The medicinal properties of mangrove plants have been recognized for centuries, with various traditional communities incorporating them into their healthcare practices. Mangroves contribute to human well-being by providing a rich source of bioactive compounds with potential therapeutic applications [3]. These compounds exhibit diverse pharmacological activities, including antioxidant, anti-inflammatory, and antimicrobial properties. Additionally, mangroves have been explored for their potential in treating various health conditions, such as wounds, skin disorders, and respiratory ailments [4]. Further, understanding and harnessing the health benefits of mangroves not only contribute to traditional medicine but also hold promise for future advancements in healthcare and pharmaceutical research.

Indonesia, with its extensive coastline and diverse ecosystems, hosts a rich array of mangrove biodiversity [5]. The mangrove forests, comprising various species such as *Rhizophora*, *Avicennia*, and *Sonneratia*, play a pivotal role in the country's coastal ecosystems [1]. Beyond their ecological significance, Indonesian mangroves have long been intertwined with traditional folk medicine practices. Local communities have recognized and utilized the medicinal properties of mangrove species for generations, relying on them to address various health issues. Different parts of mangrove plants, including leaves, bark, and roots, are employed to create remedies for ailments ranging from skin disorders to respiratory conditions [6]. The diversity of mangrove species in Indonesia offers a multitude of bioactive compounds, contributing to the pharmacological richness of traditional herbal medicine. As custodians of this biodiverse treasure trove, local communities play a vital role in preserving and passing down the knowledge of mangrove-based folk medicine.

Moreover, understanding the molecular mechanisms underlying the therapeutic properties of these mangrove plants is of paramount importance. Exploring the molecular intricacies of these bioactive compounds can elucidate the specific pathways through which they exert their medicinal effects [7]. This knowledge not only enhances the efficacy of traditional remedies but also opens avenues for scientific research and pharmaceutical development. Unraveling the molecular mechanisms of mangrove-based folk medicine not only preserves traditional knowledge but also positions these ecosystems as valuable reservoirs for the discovery of novel therapeutic agents. This integration of traditional wisdom with modern scientific understanding reinforces the importance of preserving mangrove biodiversity for the dual benefits of cultural heritage and advancements in healthcare.

Despite this, a comprehensive understanding of the mechanistic insights into the pharmacological activities of Indonesian mangrove species remains limited. Recognizing the critical need for unraveling the medicinal potential of these diverse mangroves, this study delves into the mechanisms governing their pharmacological activities. By employing various assays and methodologies, we aim to elucidate the intricate mechanisms that underscore the medicinal properties of Indonesian mangrove species, with a focus on uncovering their therapeutic potential and contributing to the broader fields of biodiversity conservation and pharmaceutical discovery. This research endeavors to bridge traditional ecological knowledge with modern scientific approaches, shedding light on the multifaceted pharmacological benefits offered by these invaluable mangrove ecosystems.

METHODS

Methods (Style subheading)

In undertaking the review, a methodological framework has been crafted to systematically gather and synthesize existing knowledge on the subject. The process involves the identification and definition of key terms crucial to the scope of the review, namely "Mangrove", "Pharmacological", and "Indonesia". Systematic searches will be

conducted across three major online databases—Science Direct, PubMed, and Google Scholar—utilizing these key terms, with stringent inclusion and exclusion criteria applied to filter relevant studies. The retrieved literature will undergo meticulous screening to ensure alignment with the review's objectives, prioritizing studies offering insights into the pharmacological activities, biological properties, and evaluations of mangrove species within the Indonesian context.

Subsequently, relevant information was extracted from selected studies, focusing on mechanistic insights into the medicinal properties of diverse Indonesian mangrove species. This data will be systematically synthesized and organized to construct a coherent narrative, highlighting key mechanistic insights, commonalities, and variations among different mangrove species. A critical analysis of the reviewed literature will be conducted, assessing the strengths and limitations of existing studies and identifying potential avenues for future research. The culmination of these efforts will result in the compilation of a comprehensive review, providing a detailed overview of the mechanistic insights into the medicinal properties of Indonesian mangrove species. Through this methodological approach, the review aims to contribute a nuanced understanding of the subject matter, bridging existing gaps in knowledge and guiding future research endeavors.

RESULTS AND DISCUSSION

Indonesia is one of the countries mega diversity of medicinal plants in the world. Indonesia's tropical forest region has 2nd highest biodiversity in the world after Brazil. There is quite a large diversity of mangroves spread across the Indonesian archipelago [86]. The investigation into the mechanistic insights of medicinal

properties of diverse mangrove species in Indonesia, as conducted through a comprehensive review, yielded a substantial volume of publications. A total of 2890 sources were identified through Google Scholar, indicating a rich landscape of scholarly works within this domain. PubMed contributed 17 publications, while Science Direct provided 13 additional sources. After accounting for potential duplications, the final count of unique publications stands at 2860, emphasizing the considerable depth and breadth of existing literature on the subject.

Upon conducting an in-depth analysis to specifically assess the relevance to mangroves, pharmacological activity, and Indonesia, a focused subset of 89 publications was identified (fig. 1). This subset encapsulates the core literature that intricately explores the mechanistic aspects of medicinal properties within Indonesian mangrove species, shedding light on their pharmacological activities. This refined set underscores the concentrated nexus between mangroves, pharmacological exploration, and the unique context of Indonesia within the broader spectrum of existing research.

The analysis of mangrove species distribution in Indonesia reveals the presence of 25 distinct mangrove species across the archipelago, with almost all species spanning across various provinces. Several species exhibit restricted distributions, such as *Aegialitis rotundifolia*, found exclusively in Java, Bali, Sulawesi, Maluku, and Papua; *Avicennia lanata* in Kalimantan and Sulawesi; *Kandelia candel* in Sumatra and Kalimantan; and *Rhizophora lamarckii* in Sumatra, Maluku, and Papua. The comprehensive distribution map, illustrated in fig. 1, provides an overview of the widespread occurrence of mangrove species throughout Indonesia, emphasizing both their ubiquity and specific regional constraints.




Fig. 1: Distribution patterns of mangrove species in Indonesia. The abbreviation of each species corresponds to its common name as follow: *Aegiceras corniculatum* (AEC), *Aegialitis rotundifolia* (AER), *Avicennia alba* (AVA), *Avicennia lanata* (AVL), *Avicennia marina* (AVM), *Avicennia officinalis* (AVO), *Bruguiera cylindrical* (BRC), *Bruguiera gymnorhiza* (BRG), *Bruguiera parviflora* (BRP), *Bruguiera sexangula* (BRS), *Ceriops decandra* (CED), *Ceriops tagal* (CET), *Excoecaria agallocha* (EXA), *Heritiera littoralis* (HEL), *Kandelia candel* (KAC), *Lumnitzera racemose* (LUR), *Nypa fruticans* (NYF), *Rhizophora apiculata* (RHA), *Rhizophora lamarckii* (RHL), *Rhizophora mucronata* (RHM), *Rhizophora stylosa* (RHS), *Sonneratia alba* (SOA), *Sonneratia caseolaris* (SOC), *Xylocarpus granatum* (XYG), and *Xylocarpus moluccensis* (XYM)

Subsequently, we conducted a more in-depth analysis focusing on the pharmacological activities and scientific evidence associated with each mangrove species. This analysis aimed to explore the potential medicinal properties of all Indonesian Mangroves species. The findings of this investigation are presented comprehensively in

table 1, which details the observed pharmacological activities and the corresponding scientific evidence supporting each species. The table provides a nuanced overview, allowing for a comprehensive understanding of the diverse therapeutic potentials inherent in these mangrove species.

Table 1: The exploration of pharmacological activities in various mangrove species

Species	Pharmacological activity and mechanism	Method	Performance IC50/MC50/IZ/Dosage	Organ	References
AEC	<ul style="list-style-type: none"> Anti-oxidant anti-inflammatory anticoagulation Antibacteria 	DPPH FRAP Lox inhibitor Prothrombin time test Rema	<ul style="list-style-type: none"> 20.49±2.14µg/ml; 33.51±1.59 µg/ml 72.80±1.20 mg/g AAE; 29.36±0.43 mg/g AAE 26.79±1.31µg/ml; 59.51±2.45µg/ml 18.19±0.13µg/ml/min; 10.33±0.14 µg/ml/min 19.53 g/ml (H37Rv strain) 26.75%; 40.13% (indometasin) of 400 mg/kg N/A 400 mg/kg 200 g/ml 100 µl** ST dan EC 173.775 µg/ml 44.68% and 35.89% (500 mg/kgBB) 200 mg/kgBW 1.18 and 0.87 mg/ml α-amilase and glukosidase respectively 	Bark; Leaf	[8, 9]
AER	<ul style="list-style-type: none"> Anti-Inflammatory Antipyretic Cytotoxic Antibacterial 	Carrageenan induction In vitro Mtt assay Disc diffusion	<ul style="list-style-type: none"> 26.75%; 40.13% (indometasin) of 400 mg/kg N/A 400 mg/kg 200 g/ml 100 µl** ST dan EC 	Leaf	[10-12]
AVA	<ul style="list-style-type: none"> iCytotoxic Cytotoxic Anti diarrheal Antipyretic Antidiabetic 	MTT Assay with widr cells MCF7 and Hela Cells Castor oil induction Yeast induction Inhibition of amylase glucosidase)	<ul style="list-style-type: none"> 173.775 µg/ml 44.68% and 35.89% (500 mg/kgBB) 200 mg/kgBW 1.18 and 0.87 mg/ml α-amilase and glukosidase respectively 	Leaf	[13-17]
AVL	Cytotoxic	Widr cells	305.928 µg/ml	Leaf	[16, 18-21]
AVM	<ul style="list-style-type: none"> Antibacterial Antimutagenic Anti-inflammatory Antiviral Antioxidants 	Agar diffusion MTT assay Mouse model of rheumatoid arthritis In vitro DPPH, hydroxyl, superoxide and abts)	<ul style="list-style-type: none"> N/A N/A N/A N/A N/A 	Leaf	[16, 18-21]
AVO	<ul style="list-style-type: none"> Antioxidants Antimicrobes Antiulcers Diuretics Lipschitz Cytotoxic Antidiabetic 	DPPH; ABTS Disc diffusion Indomethacine induction In vivo In vitro Inhibition of amylase and glucosidase)	<ul style="list-style-type: none"> 4077±3.43µg/ml; 38.8±9.62 µg/ml 7.8±0.7; 7.0±0.1; and 7.7±0.5E mm to E. coli; S. mutans; and S. Aureus respectively N/A 200 mg/kg 131.2µg/ml 0.66±0.05 and 0.71±0.1 mg/ml for amylase and glucosidase respectively 	Leaf	[13, 22-26]
BRC	<ul style="list-style-type: none"> Antioxidants Antidiabetic Antimicrobials 	DPPH STZ-induction Disc diffusion	<ul style="list-style-type: none"> 175 µg/ml; 162.5 µg/ml 5 mg/ml 14.30 and 13.30 mm for S. aureus and E. Coli respectively 	Leaf; Bark	[27-34]
BRG	<ul style="list-style-type: none"> Antihyperglycemic Antimicrobial Anti-inflammatory Hepatoprotective Anti-Hemolytic Antioxidants 	STZ-induction In vitro COX inhibition test Induction of gain	<ul style="list-style-type: none"> 400 mg/kg reduced in day 28th N/A 22 dan 23 mm to E. Coli dan S. Aureus respectively 113.79±0.16(µg/ml 125 mg/kg 105.00 µg/ml 	Leaf	[35]
BRP	Antioxidant	DPPH-In vitro	N/A	Leaf	[36]
BRS	Antibacterial	Agar diffusion	N/A	Leaf	[37-39]
CED	<ul style="list-style-type: none"> Anti-inflammatory Antibacterial 	Carrageenan induction	400 mg/kg	Leaf	[37-39]
CET	<ul style="list-style-type: none"> Antioxidants Anti-cancer Antibacterial and diuretic 	Agar diffusion DPPH; FRAP In vitro Agar diffusion	<ul style="list-style-type: none"> 2.1±0.28 µg/ml (10 mm) 95 µg/ml; 4 mmol AAE/g 4.18±0.45 µg/ml and 80.04±0.19 µg/ml to Hela and MDA-MB231respectively 5.0±0.1 mm to P. aeruginosa and 500 mg/kg (diuresis) 	Leaf	[40-43]
EXA	<ul style="list-style-type: none"> Antioxidants Anti-inflammatory Analgesic Anti cancer Anti bacterial 	Dpph Carrageenan induction Acetic acid induction MTT assay Agar diffusion	<ul style="list-style-type: none"> 67.50 µg/µl 500 mg/kg 500 mg/kg 4 and 7 mg/ml for Capan-1 and Miapaca-2 respectively 10.3±2.7; 6.2±0.8; 8.3±1.2 dan 8.5±0.7 mm for E. Coli, A. tumefaciens, S. mutans, and S. Aureus r 	Leaf	[23, 44-47]
HEL	<ul style="list-style-type: none"> Antioxidants Anti-haemolytic Anti-bacterial Anti-inflammatory 	DPPH; FRAP Agar diffusion DDS 3% induction	<ul style="list-style-type: none"> 121.23±0.32µg/ml and 101.11 ± 0.41 mmol equivalent Fe (II)/gram 526.90±25.85µg/ml 16.1±0.17, 15.8±0.44 and 17.6±0.44 mm for E. coli, S. Aureus and S. enterica respectively 	Leaf	[48, 49]
KAC	<ul style="list-style-type: none"> Anti-Inflammatory Antioxidant Antidiabetic 	DPPH Inhibition glucosidase	<ul style="list-style-type: none"> 1,7±0,1µM 86.01±0.31% 206.89 µg/ml 	Leaf	[50-52]
LUR	<ul style="list-style-type: none"> Antioxidant Cytotoxicity Hepatoprotective Antidiabetic Anticancer 	DPPH and ABTS MTT assay on Hep G2 cancer cells Inhibition of amylase and glucosidase MCF7 and hela cells	<ul style="list-style-type: none"> 38.89 µg/ml; 44.38 µg/ml 26.05 µg/ml 300 mg/kgBB 3.064±0,022 and 3.01±0,041 µg/ml for amylase and glucosidase respectively 26.05 and 195.1 µg/ml for MCF7 and HeLa cells respectively 	Leaf	[14, 53-55]
NYF	<ul style="list-style-type: none"> Antioxidant Antidiabetic Anti-bacterial 	DPPH Intraperitoneal glucose tolerance test Disk diffusion	<ul style="list-style-type: none"> 2.770±0.012 mg/ml 56,6% 6.5±0.4; 7.3±0.5; 6.25±0.3, and 6.8±0.3 mm for E. Coli, A. tumefaciens, S. mutans, and S. Aureus respectively 	Leaf	[23, 56]

Species	Pharmacological activity and mechanism	Method	Performance IC50/MC50/IZ/Dosage	Organ	References
RHA	<ul style="list-style-type: none"> Antioxidants Anti bacterial Anti Inflammatory Anti Cancer 	DPPH; ABTS Disk diffusion Carrageenan induction MTT assay	<ul style="list-style-type: none"> 9.31±1.56; 3.01±0.75 µg/ml 14 and 9 mm for <i>B. cereus</i> and <i>S. saprophyticus</i> respectively 0.39± 0.04 mm 12.06 µg/ml (HepG2) N/A 	Leaf Leaf Leaf Leaf	[57-59]
RHLI	<ul style="list-style-type: none"> Alzheimer's disease 				[60]
RHM	<ul style="list-style-type: none"> Antioxidants Anti-inflammatory Anti-cholinesterase Anti-cholinesterase Antidiabetic Antidiabetic Antibacterial Heptoprotective 	DPPH; ABTS Inhibition of cox-1 and COX-2 <i>In vitro</i> Aloxane-induced diabetic rats STZ induction Disk diffusion	<ul style="list-style-type: none"> 0.38±0.03 mg/ml; 1.25±0.01 mg/ml 1.42±0.01 COX-1; and 1.38±0.00 mg/ml COX-2 59.31 ± 0.35 µg/ml 60 mg/kg in 30 days 100 mg/kg 9.97±0.17, 19.56±0.19, 15.74±0.06, 11.31±0.25, 5.63±0.06, and 16.57±0.22 mm for <i>B. Subtilis</i>, <i>SAureus</i>, <i>S. Faecalis</i>, <i>S. Pyogenes</i>, <i>E. Coli</i>, and <i>P. Aeruginosa</i> respectively 300 mg/kgbw 9.56 µg/ml 2.69 µg/ml 51.0 µg/ml 12.5 mm(<i>S. aureus</i>) and 12.5 mm (<i>B. Cereus</i>) 14.0 µg/ml 14.94 µg/ml (Hexane) Bacillus cereus (10 mm), Bacillus subtilis (11 mm), Sarcina lutea (12 mm), Pseudomonas aeruginosa (10 mm) and Shigella dysenteriae (12 mm) 	Leaf Leaf Leaf Leaf Leaf Leaf Leaf	[54, 61-65]
RHS	<ul style="list-style-type: none"> Anti-cholinesterase Antioxidants Anti cancer 	<i>In vitro</i> DPPH MTT assay	<ul style="list-style-type: none"> 5.10 µg/ml 12.5 mm(<i>S. aureus</i>) and 12.5 mm (<i>B. Cereus</i>) 	Leaf Leaf	[59, 66, 67]
SOA	<ul style="list-style-type: none"> Anti-bacterial Antioxidants Cytotoxic Antimicrobial Antidiabetic 	Disk diffusion DPPH Disk diffusion <i>In vivo</i>	<ul style="list-style-type: none"> 14.0 µg/ml 14.94 µg/ml (Hexane) Bacillus cereus (10 mm), Bacillus subtilis (11 mm), Sarcina lutea (12 mm), Pseudomonas aeruginosa (10 mm) and Shigella dysenteriae (12 mm) 	Bark Leaf Leaf	[68-70]
SOCs	<ul style="list-style-type: none"> Antimicrobial Antioxidants Anti-cholinesterase Antidiabetic Anti-inflammation Analgesics Cytotoxic Anti-diarrhea 	Disk diffusion DPPH <i>In vitro</i> Inhibition of α-amylase and OGTT Carrageenan induction Acetic acid induction Castor oil induction	<ul style="list-style-type: none"> B. subtilis (18.33±0.76 mm), <i>B. coagulans</i> (19.50±0.50 mm) and <i>P. vulgaris</i> (12.67±0.58 mm) 21.74 µg/ml 5.87 µg/ml and 37.6 µg/ml 58.24% at 200 mg/kgbb 78.23 % at 200 mg/kgbb 25.0±0.05 µg/ml 250 mg/kg 50 µg m/l, and (MIC) 10 µg m/l. 0.041, 0.039, 0.096, and 0.235 mg/ml 0.25 and 0.16 mg/ml HIV-1 15.98 ± 6.87 µM and IAV 14.02 ± 3.54 µM 10 µM 0.239 µg/ml 	Leaf Leaf Leaf Leaf Leaf Leaf Leaf Leaf Leaf Leaf	[71-76]
XYG	<ul style="list-style-type: none"> Antimalarials Antioxidants Antidiabetic Antiviral Anticancer Antifilarial Antimicrobial 	Plasmodium falciparum DPPH, ABTS, superoxide and hydrogen peroxide scavenging) Inhibition of amylase and glucosidase HIV-1 and IAV A549 <i>Brugia malayi</i> Agar disc diffusion	<ul style="list-style-type: none"> 0.041, 0.039, 0.096, and 0.235 mg/ml 0.25 and 0.16 mg/ml HIV-1 15.98 ± 6.87 µM and IAV 14.02 ± 3.54 µM 10 µM 0.239 µg/ml 	Leaf Leaf Leaf Leaf Leaf	[17, 26, 40, 77-80]
XYM	<ul style="list-style-type: none"> Anti-cancer Anti-bacterial Antioxidant Cytotoxic Anti-cholinesterase Anti-cancer Antidiabetic 	(MTT assay against AGS, HT-29 and MDA-MB-435S cells) Disk Diffusion DPPH <i>In vitro</i> MTT cell assay hepg2 Inhibition of amylase	<ul style="list-style-type: none"> 0.62, 2.5, 1.08 µg/ml <i>S. Aureus</i> 12.7±1.2 mm and <i>E. Coli</i> 11.9±0.9 mm 0.000154. 2.0 x 105 ppm 21 µg/ml 25.12 µg/ml 28.4 µg/ml 	Leaf Leaf Leaf Leaf Leaf Leaf	[81-85]

*DPPH: 2,2-diphenyl-1-picrylhydrazyl; FRAP: Ferric Reducing Antioxidant Power; LOX: lipoxygenase; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ABTS: 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); DDS: dextran sulfate sodium; COX: Cyclooxygenase; STZ: Streptozotocin; HIV: Human Immunodeficiency Virus; IC: Inhibitor Concentration; MC: Minimal Concentration; IZ: Inhibitor Zone. *Aegiceras corniculatum* (AEC), *Aegialitis rotundifolia* (AER), *Avicennia alba* (AVA), *Avicennia lanata* (AVL), *Avicennia marina* (AVM), *Avicennia officinalis* (AVO), *Bruguiera cylindrical* (BRC), *Bruguiera gymnorhiza* (BRG), *Bruguiera parviflora* (BRP), *Bruguiera sexangula* (BRS), *Ceriops decandra* (CED), *Ceriops tagal* (CET), *Excoecaria agallocha* (EXA), *Heritiera littoralis* (HEL), *Kandelia candel* (KAC), *Lumnitzera racemose* (LUR), *Nypa fruticans* (NYF), *Rhizophora apiculata* (RHA), *Rhizophora lamarckii* (RHL), *Rhizophora mucronata* (RHM), *Rhizophora stylosa* (RHS), *Sonneratia alba* (SOA), *Sonneratia caseolaris* (SOC), *Xylocarpus granatum* (XYG), and *Xylocarpus moluccensis* (XYM).

The exploration of pharmacological activities in various mangrove species across Indonesia has uncovered a rich array of bioactive compounds with promising therapeutic applications. From the table above, it can be seen that the Rhizophora family has pharmacological activities, one of which is anti-cancer. This type of mangrove has cytotoxic activity because it contains active chemical compounds, including phenolic compounds, flavonoids, terpenoids and saponins [87]. Among the diverse species studied, a notable convergence is observed in their antioxidant properties. Species like *Aegiceras corniculatum*, *Avicennia marina*, and *Rhizophora mucronata* exhibit potent antioxidant effects, as demonstrated through assays such as DPPH, ABTS, and FRAP (fig. 2). This shared characteristic underscores the potential for collective medicinal benefits, emphasizing the importance of a holistic approach to harnessing the healing potential of mangrove ecosystems.

Another significant finding emerges in the realm of anti-inflammatory activities. *Aegialitis rotundifolia*, *Ceriops decandra*, and *Rhizophora apiculata*, among others, showcase promising anti-inflammatory effects, inhibiting enzymes like LOX and responding positively to carrageenan induction. This diversity in anti-inflammatory responses across mangrove species opens avenues for targeted therapeutic interventions, highlighting the importance of considering multiple species for their cumulative health benefits. Moreover, the study reveals a commonality in antibacterial effects, as evidenced by species like *Avicennia marina*, *Ceriops tagal*, and *Excoecaria agallocha*, which exhibit potent antibacterial properties in agar diffusion assays (fig. 2). These findings collectively emphasize the potential of mangrove species in combating microbial infections. In conclusion, the shared pharmacological activities observed in diverse mangrove species highlight the need for comprehensive exploration and utilization of these ecosystems in traditional and modern medicine, paving the way for novel drug development and therapeutic interventions.




Fig. 2: The representative correlation between pharmacological activity and species in a chord diagram reflects the complex relationship between biological effects and various types of species

CONCLUSION

The investigation into pharmacological activities across diverse mangrove species in Indonesia reveals a notable convergence in antioxidant mechanisms, exemplified by *Aegiceras corniculatum*, *Avicennia marina*, and *Rhizophora mucronata*. Additionally, diverse anti-inflammatory responses are observed in species like *Aegialitis rotundifolia*, *Ceriops decandra*, and *Rhizophora apiculata*, emphasizing opportunities for targeted therapeutic interventions. The commonality in antibacterial effects, seen in *Avicennia marina*, *Ceriops tagal*, and *Excoecaria agallocha*, underscores the potential of mangrove species in combating microbial infections through distinct antibacterial mechanisms. In conclusion, the shared pharmacological activities highlight the need for a comprehensive exploration of mechanisms, offering insights for novel drug development and therapeutic interventions by leveraging the intricate properties of these ecologically crucial ecosystems.

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to Universitas Muhammadiyah Surakarta, specifically the Doctoral Program, and Universitas Muhammadiyah Pekajangan Pekalongan, for their financial support during the course of this study.

AUTHORS CONTRIBUTIONS

All authors have contributed equally

CONFLICT OF INTERESTS

Declared none

REFERENCES

- Kathiresan K, Bingham BL. Biology of mangroves and mangrove ecosystems. *Adv Mar Biol.* 2001;40:81-251. doi: [10.1016/S0065-2881\(01\)40003-4](https://doi.org/10.1016/S0065-2881(01)40003-4).
- Awuku Sowah EM, Graham NA, Watson NM. Investigating mangrove human health relationships: a review of recently reported physiological benefits. *Dialogues Health.* 2022;1:100059. doi: [10.1016/j.dialog.2022.100059](https://doi.org/10.1016/j.dialog.2022.100059), PMID 38515922.
- Dahibhate NL, Saddhe AA, Kumar K. Mangrove plants as a source of bioactive compounds: a review. *Nat Prod J.* 2019;9(2):86-97. doi: [10.2174/221031550866180910125328](https://doi.org/10.2174/221031550866180910125328).
- Mahmud I, Islam MK, Saha S, Barman AK, Rahman MM, Anisuzzman M. Pharmacological and ethnomedicinal overview of heritiera fomes: future prospects. *Int Sch Res Notices.* 2014;2014:938543. doi: [10.1155/2014/938543](https://doi.org/10.1155/2014/938543), PMID 27382611.
- Spalding M. World atlas of mangroves. Routledge; 2010.
- Arbiastutie Y, Diba F, Masriani M. Short communication: ethnobotanical and ecological studies of medicinal plants in a mangrove forest in Mempawah District west Kalimantan Indonesia. *Biodiversitas.* 2021;22(6). doi: [10.13057/biodiv/d220619](https://doi.org/10.13057/biodiv/d220619).
- Zhang W, Zeng Y, Jiao M, YE C, LI Y, Liu C. Integration of high throughput omics technologies in medicinal plant research: the new era of natural drug discovery. *Front Plant Sci.* 2023;14:1073848. doi: [10.3389/fpls.2023.1073848](https://doi.org/10.3389/fpls.2023.1073848), PMID 36743502.
- Janmanchi H, Raju A, Degani MS, Ray MK, Rajan MG. Antituberculosis antibacterial and antioxidant activities of aegiceras corniculatum a mangrove plant and effect of various extraction processes on its phytoconstituents and bioactivity. *S Afr J Bot.* 2017;113:421-7. doi: [10.1016/j.sajb.2017.09.019](https://doi.org/10.1016/j.sajb.2017.09.019).
- Biswas R, Rahman SM, Didarul Islam KM, Billah MM, Aunjun A, Nurunnabi TR. Antioxidant anti-inflammatory and anticoagulation properties of *Aegiceras corniculatum* and *acanthus ilicifolius*. *Pharm Biomed Res.* 2019;5(3):35-44. doi: [10.18502/pbr.v5i3.2117](https://doi.org/10.18502/pbr.v5i3.2117).
- Santos MJ. Biological research marks its 50th y by joining bio med central. *Biol Res.* 2014 Mar 26;47(1):1. doi: [10.1186/0717-6287-47-1](https://doi.org/10.1186/0717-6287-47-1), PMID 25026971.

11. Reddy A, Grace JR. Anticancer activity of methanolic extracts of selected mangrove plants. *Int J Pharm Sci Res.* 2016;7(9):3852. doi: [10.13040/IJPSR.0975-8232.7\(9\).3852-56](https://doi.org/10.13040/IJPSR.0975-8232.7(9).3852-56).
12. Hasan I, Hussain MS, Millat MS, Sen N, Rahman MA, Rahman MA. Ascertainment of pharmacological activities of *Allamanda nerifolia* hook and *aegialitis rotundifolia* roxb used in Bangladesh: an *In vitro* study. *J Tradit Complement Med.* 2018;8(1):107-12. doi: [10.1016/j.jtcme.2017.03.005](https://doi.org/10.1016/j.jtcme.2017.03.005), PMID 29321997.
13. Hossain ML. Medicinal activity of *Avicennia officinalis*: evaluation of phytochemical and pharmacological properties. *Saudi J Med Pharm Sci.* 2016;2:250-5.
14. Eswaraiah G, Peele KA, Krupanidhi S, Kumar RB, Venkateswarlu TC. identification of bioactive compounds in leaf extract of *avicennia alba* by GC-MS analysis and evaluation of its *In vitro* anticancer potential against MCF7 and hela cell lines. *J King Saud Univ Sci.* 2020;32(1):740-4. doi: [10.1016/j.jksus.2018.12.010](https://doi.org/10.1016/j.jksus.2018.12.010).
15. Rahman M, Biswas S, Bala V, Shill A, Bose U. Antidiarrhoeal and antinociceptive activities of leafs *avicennia alba*. *Pharmacologyonline.* 2011;1:492-500.
16. Karami L, Majd A, Mehrabian S, Nabiuni M, Salehi M. Irian s: antimutagenic and anticancer effects of *Avicennia marina* leaf extract on *salmonella typhimurium* TA100 bacterium and human promyelocytic leukaemia HL-60 cells. *Sci Asia.* 2012;38(3):349-55.
17. Das SK, Dash S, Thatoi H, Patra JK. *In vitro* α -amylase and α -glucosidase inhibition antioxidant anti-inflammatory activity and GC-MS profiling of *Avicennia alba* blume. *Comb Chem High Throughput Screen.* 2020;23(9):945-54. doi: [10.2174/1386207323666200428081748](https://doi.org/10.2174/1386207323666200428081748), PMID 32342807.
18. Illian D, Basyuni M, Wati R, Zaitun Hasibuan P. Polyisoprenoids from *avicennia marina* and *Avicennia lanata* inhibit WiDr cells proliferation. *Phcog Mag.* 2018;14(58):513-8. doi: [10.4103/pm.pm_201_18](https://doi.org/10.4103/pm.pm_201_18).
19. Sharief M, Srinivasulu A, Chittibabu B, Umamaheswararao V. Identification of bioactive principles of *Avicennia officinalis* fruit extract in methanol and screening for antibacterial activity. *Int J Pharm Sci Drug Res.* 2015;7(1):73-7.
20. Shafie M, Forghani A, Moshtaghian J. Anti-inflammatory effects of hydro-alcoholic extracts of mangrove (*Avicennia marina*) and vitamin C on arthritic rats. *Boll Environ Pharmacol Life Sci.* 2013;2:32-7.
21. Beula JM, Gnanesigan M, Rajkumar PB, Ravikumar S, Anand M. Antiviral antioxidant and toxicological evaluation of mangrove plant from South East Coast of India. *Asian Pac J Trop Biomed.* 2012;2(1):S352-7. doi: [10.1016/S2221-1691\(12\)60187-7](https://doi.org/10.1016/S2221-1691(12)60187-7).
22. Thirunavukkarasu P, Ramanathan T, Ramkumar L, Shannugapriya R, Renugadevi G. The antioxidant and free radical scavenging effect of *Avicennia officinalis*. *J Med Plants Res.* 2011;5(19):4754-8.
23. Bakshi M, Chaudhuri P. Antimicrobial potential of leaf extracts of ten mangrove species from Indian Sundarban. *Int J Pharm Biol Sci.* 2014;5(1):294-304.
24. Sura S, Anbu J, Sultan M, Uma B. Antiulcer effect of ethanolic leaf extract of *Avicennia officinalis*. *Pharmacologyonline.* 2011;3:12-9.
25. Hossain MH, Howlader MS, Dey SK, Hira A, Ahmed A. Evaluation of diuretic and neuropharmacological properties of the methanolic extract of *Avicennia officinalis* l leaves from Bangladesh. *Int J Pharm Phytopharmacl Res.* 2012;2:2-6.
26. Das SK, Samantaray D, Sahoo SK, Patra JK, Samanta L, Thatoi H. Bioactivity-guided isolation and structural characterization of the antidiabetic and antioxidant compound from bark extract of *Avicennia officinalis* l. *S Afr J Bot.* 2019;125:109-15. doi: [10.1016/j.sajb.2019.07.011](https://doi.org/10.1016/j.sajb.2019.07.011).
27. Gawali P, Jadhav B. Antioxidant activity and antioxidant phytochemical analysis of mangrove species *Sonneratia alba* and *Bruguiera cylindrica*. *Asian J Microbiol Biotechnol Environ Sci.* 2011;13(2):257-61.
28. Pitchaipillai R, Ponniah T. *In vitro* antidiabetic activity of ethanolic leaf extract of *Bruguiera cylindrica* l glucose uptake by yeast cells method. *Int Biol Biomed J.* 2016;2(4):171-5.
29. Audah K, Amsyir J, Almasyhur F, Hapsari A, Sutanto H. Development of extract library from Indonesian biodiversity: exploration of antibacterial activity of mangrove *Bruguiera cylindrica* leaf extracts. *IOP Conf S Earth Environ Sci.* 2018;130(1):012025. doi: [10.1088/1755-1315/130/1/012025](https://doi.org/10.1088/1755-1315/130/1/012025).
30. Karimulla S, Kumar BP. Antidiabetic and antihyperlipidemic activity of bark of *Bruguiera gymnorhiza* on streptozotocin-induced diabetic rats. *Asian J Pharm Sci Technol.* 2011;1(1):4-7. doi: [10.13140/RG.2.2.10470.04163](https://doi.org/10.13140/RG.2.2.10470.04163).
31. Seepana R, Perumal K, Kada NM, Chatragadda R, Raju M, Annamalai V. Evaluation of antimicrobial properties from the mangrove rhizophora apiculata and *Bruguiera gymnorhiza* of burmanallah coast South Andaman India. *J Coast Life Med.* 2016;4(6):475-8. doi: [10.12980/jclm.4.2016j6-52](https://doi.org/10.12980/jclm.4.2016j6-52).
32. Barik R, Sarkar R, Biswas P, Bera R, Sharma S, Nath S. 5,7-dihydroxy-2-(3-hydroxy-4, 5-dimethoxy-phenyl)-chromen-4-one-a flavone from *Bruguiera gymnorhiza* displaying anti-inflammatory properties. *Indian J Pharmacol.* 2016;48(3):304-11. doi: [10.4103/0253-7613.182890](https://doi.org/10.4103/0253-7613.182890), PMID 27298502.
33. Karim MA, Islam MA, Islam MM, Rahman MS, Sultana S, Biswas S. Evaluation of antioxidant anti-hemolytic cytotoxic effects and antibacterial activity of selected mangrove plants (*Bruguiera gymnorhiza* and *Heritiera littoralis*) in Bangladesh. *Clin Phytosci.* 2020;6(1):1-12.
34. Sur TK, Hazra A, Hazra AK, Bhattacharyya D. Antioxidant and hepatoprotective properties of Indian Sunderban mangrove *Bruguiera gymnorhiza* l leave. *J Basic Clin Pharm.* 2016;7(3):75-9. doi: [10.4103/0976-0105.183262](https://doi.org/10.4103/0976-0105.183262), PMID 27330259.
35. Bunyaphraphatsara N, Jutiviboonsuk A, Sornlek P, Therathanathorn W, Aksornkaew S, Fong HH. Pharmacological studies of plants in the mangrove forest. *Thai J Phytopharmacy.* 2003;10(2):2.
36. Abeysinghe PD. Antibacterial activity of some medicinal mangroves against antibiotic-resistant pathogenic bacteria. *Indian J Pharm Sci.* 2010;72(2):167-72. doi: [10.4103/0250-474X.65019](https://doi.org/10.4103/0250-474X.65019), PMID 20838519.
37. Hossain H, Moniruzzaman S, Nimmi I, Kawsar H, Hossain A, Islam A. Anti-inflammatory and antioxidant activities of the ethanolic extract of *Ceriops decandra* (Griff.) ding hou bark. *Orient Pharm Exp Med.* 2011;11(4):215-20. doi: [10.1007/s13596-011-0037-z](https://doi.org/10.1007/s13596-011-0037-z).
38. Krishnamoorthy M, Sasikumar JM, Shamna R, Pandiarajan C, Sofia P, Nagarajan B. Antioxidant activities of bark extract from mangroves *Bruguiera cylindrica* (L.) Blume and *Ceriops decandra* Perr. *Indian J Pharmacol.* 2011;43(5):557-62. doi: [10.4103/0253-7613.84972](https://doi.org/10.4103/0253-7613.84972), PMID 22022000.
39. Saravanan D, Radhakrishnan M. Antimicrobial activity of mangrove leaves against drug-resistant pathogens. *Int J PharmTech Res.* 2016;9(1):141-6.
40. Zhou HC, Tam NF, Lin YM, Ding ZH, Chai WM, Wei SD. Relationships between degree of polymerization and antioxidant activities: a study on proanthocyanidins from the leaves of a medicinal mangrove plant *Ceriops tagal*. *Plos One.* 2014;9(10):e107606. doi: [10.1371/journal.pone.0107606](https://doi.org/10.1371/journal.pone.0107606), PMID 25313980.
41. Sachithanandam V, Parthiban A, Lalitha P, Muthukumaran J, Jain M, Elumalai D. Biological evaluation of gallic acid and quercetin derived from *Ceriops tagal*: insights from extensive *In vitro* and *in silico* studies. *J Biomol Struct Dyn.* 2022;40(4):1490-502. doi: [10.1080/07391102.2020.1828173](https://doi.org/10.1080/07391102.2020.1828173), PMID 32996435.
42. Arivuselvan N, Durai Silambarasan T, Govindan K, Kathiresan. antibacterial activity of mangrove leaf and bark extracts against human pathogens. *Adv Biol Res.* 2011 Jan;5(5):251-4.
43. Biswas B, Golder M, Abid MA, Mazumder K, Sadhu SK. Terpenoids-enriched ethanol extracts of aerial roots of *Ceriops decandra* (Griff.) and *Ceriops tagal* (Perr.) promote diuresis in mice. *Heliyon.* 2021;7(7):e07580. doi: [10.1016/j.heliyon.2021.e07580](https://doi.org/10.1016/j.heliyon.2021.e07580), PMID 34337186.
44. Plant LM. *In vitro* antioxidant analysis and the DNA damage protective activity of leaf extract of the *Excoecaria agallocha*. *Int J Agric Chem.* 2012;1(4).
45. Babuselvam M, Ravikumar S, Farook KM, Abideen S, Mohamed MP, Uthiraselvam M. Evaluation of anti-inflammatory and analgesic effects on the extracts of different parts of *Excoecaria agallocha* l. *J App Pharm Sci.* 2012;2(9):108-12. doi: [10.7324/JAPS.2012.2921](https://doi.org/10.7324/JAPS.2012.2921).

46. Mondal S, Ghosh D, Ramakrishna K. A complete profile on blind your eye mangrove *Excoecaria agallocha* L (Euphorbiaceae): ethnobotany, phytochemistry and pharmacological aspects. *Pharmacogn Rev*. 2016;10(20):123-38. doi: [10.4103/0973-7847.194049](https://doi.org/10.4103/0973-7847.194049), PMID [28082796](#).
47. Patil R, Manohar SM, Upadhye MV, Katchi V, Rao AJ, Mule A. Anti reverse transcriptase and anticancer activity of stem ethanol extracts of *Excoecaria agallocha* (Euphorbiaceae). *Ceylon J Sci (Biol Sci)*. 2011;40(2):147-55. doi: [10.4038/cjsbs.v40i2.3931](https://doi.org/10.4038/cjsbs.v40i2.3931).
48. Christopher R, Nyandoro SS, Chacha M, de Koning CB. A new cinnamoylglycoside from Heritiera littoralis leaf extracts. *Nat Prod Res*. 2014;28(6):351-8. doi: [10.1080/14786419.2013.863202](https://doi.org/10.1080/14786419.2013.863202), PMID [24443810](#).
49. Lin G, Li M, Xu N, Wu X, Liu J, Wu Y. Anti-inflammatory effects of *Heritiera littoralis* fruits on dextran sulfate sodium (DSS)-induced ulcerative colitis in mice by regulating gut microbiota and suppressing NF- κ B pathway. *BioMed Res Int*. 2020;2020:8893621. doi: [10.1155/2020/8893621](https://doi.org/10.1155/2020/8893621), PMID [33354574](#).
50. Dat LD, Thao NP, Tai BH, Luyen BT, Yang SY, Kim S. Anti-inflammatory triterpenes and glyceryl glycosides from *Kandelia candel* (L.) druce. *Nat Prod Sci*. 2015;21(3):150-4.
51. Madagi SB, Hoskeri JH, Vedamurthy AB. Phytochemical profiling *In vitro* antioxidant and anti-inflammatory activities of *Hopea ponga*, *Kandelia candel*, *Vitex leucoxylon* and *Rhizophora apiculata*. *J Pharmacogn Phytochem*. 2018;7(6):1425-40.
52. Shettar AK, Vedamurthy AB. An *In vitro* approach for evaluating anthelmintic activity of *Kandelia candel* and *Rhizophora apiculata*. *J Pharmacogn Phytochem*. 2017;6(1):5-9.
53. Paul T, Ramasubbu S. The antioxidant anticancer and anticoagulant activities of *Acanthus ilicifolius* L roots and *Lumnitzera racemosa* wild leaves from southeast coast of India. *J Appl Pharm Sci*. 2017;7(3):81-7.
54. Ravikumar S, Gnanadesigan M. Hepatoprotective and antioxidant activity of a mangrove plant *Lumnitzera racemosa*. *Asian Pac J Trop Biomed*. 2011;1(5):348-52. doi: [10.1016/S2221-1691\(11\)60078-6](https://doi.org/10.1016/S2221-1691(11)60078-6), PMID [23569791](#).
55. Paswan R, Jadhav B, Dhavan P, Patel P. *In vitro* antidiabetic activity and phytochemical analysis of *Lumnitzera racemosa* leaves. *Education*. 2015;2020.
56. Yusoff NA, Yam MF, Beh HK, Abdul Razak KN, Widyawati T, Mahmud R. Antidiabetic and antioxidant activities of *Nypa fruticans* Wurmb vinegar sample from Malaysia. *Asian Pac J Trop Med*. 2015;8(8):595-605. doi: [10.1016/j.apjtm.2015.07.015](https://doi.org/10.1016/j.apjtm.2015.07.015), PMID [26321511](#).
57. Gao M, Xiao H. Activity guided isolation of antioxidant compounds from *Rhizophora apiculata*. *Molecules*. 2012;17(9):10675-82. doi: [10.3390/molecules170910675](https://doi.org/10.3390/molecules170910675), PMID [22955456](#).
58. Prabhu VV, Guruvayoorappan C. Anti-inflammatory and anti-tumor activity of the marine mangrove *Rhizophora apiculata*. *J Immunotoxicol*. 2012;9(4):341-52. doi: [10.3109/1547691X.2012.660997](https://doi.org/10.3109/1547691X.2012.660997), PMID [22800297](#).
59. Hong LS, Ibrahim D, Kassim J. Assessment of *in vivo* and *In vitro* cytotoxic activity of hydrolysable tannin extracted from *Rhizophora apiculata* barks. *World J Microbiol Bio Technol*. 2011;27(11):2737-40. doi: [10.1007/s11274-011-0727-1](https://doi.org/10.1007/s11274-011-0727-1).
60. Laith AA. Phytochemical analysis and antimicrobial activities of mangrove plant (*Rhizophora apiculata*) against selected fish pathogenic bacteria. *IOP Conf Ser: Earth Environ Sci*. 2021;718(1):012076. doi: [10.1088/1755-1315/718/1/012076](https://doi.org/10.1088/1755-1315/718/1/012076).
61. Chakraborty K, Raola VK. Two rare antioxidant and anti-inflammatory oleanenes from loop root asiatic mangrove *Rhizophora mucronata*. *Phytochemistry*. 2017;135:160-8. doi: [10.1016/j.phytochem.2016.12.013](https://doi.org/10.1016/j.phytochem.2016.12.013), PMID [28062072](#).
62. Suganthi N, Devi KP. *In vitro* antioxidant and anti-cholinesterase activities of *Rhizophora mucronata*. *Pharm Biol*. 2016;54(1):118-29. doi: [10.3109/13880209.2015.1017886](https://doi.org/10.3109/13880209.2015.1017886), PMID [25856713](#).
63. Hardoko ES, Puspitasari Y, Amalia R. Study of ripe *Rhizophora mucronata* fruit flour as a functional food for antidiabetic. *Int Food Res J*. 2015;22(3):953-9.
64. Sur TK, Hazra AK, Bhattacharyya D, Hazra A. Antiradical and antidiabetic properties of standardized extract of sunderban mangrove *Rhizophora mucronata*. *Pharmacogn Mag*. 2015;11(42):389-94. doi: [10.4103/0973-1296.153094](https://doi.org/10.4103/0973-1296.153094), PMID [25829780](#).
65. Gurudeeban S, Ramanathan T, Satyavani K. Antimicrobial and radical scavenging effects of alkaloid extracts from *Rhizophora mucronata*. *Pharm Chem J*. 2015;49(1):34-7. doi: [10.1007/s11094-015-1218-8](https://doi.org/10.1007/s11094-015-1218-8).
66. Wahyuni WT, Darusman LK, Surya NK. Potency of rhizopora spp extracts as antioxidant and inhibitor of acetylcholinesterase. *Procedia Chem*. 2015;16:681-6. doi: [10.1016/j.proche.2015.12.009](https://doi.org/10.1016/j.proche.2015.12.009).
67. Miranti DI, Ichiiura H, Ohtani Y. The bioactive compounds and antioxidant activity of food products of *Rhizophora stylosa* fruit (coffee and tea mangrove). *Int J For Res*. 2018;2018:1-6. doi: [10.1155/2018/2315329](https://doi.org/10.1155/2018/2315329).
68. Saad S, Taher M, Susanti D, Qaralleh H, Awang AF. *In vitro* antimicrobial activity of mangrove plant *Sonneratia alba*. *Asian Pac J Trop Biomed*. 2012;2(6):427-9. doi: [10.1016/S2221-1691\(12\)60069-0](https://doi.org/10.1016/S2221-1691(12)60069-0), PMID [23569943](#).
69. Milon MA, Muhit MA, Goshwami D, Masud MM, Begum B. Antioxidant cytotoxic and antimicrobial activity of *Sonneratia alba* bark. *Int J Pharm Sci Res*. 2012;3(7):2233.
70. Morada NJ, Metillo EB, Uy MM, Oclarit JM. Antidiabetic polysaccharide from mangrove plant *Sonneratia alba* Sm. In: Proceedings of the international conference on Asia agriculture and animal international proceedings of chemical biological and environmental engineering; 2011. p. 197-200.
71. Simlai A, Rai A, Mishra S, Mukherjee K, Roy A. Antimicrobial and antioxidant activities in the bark extracts of *Sonneratia caseolaris* a mangrove plant. *Excli J*. 2014;13:997-1010. PMID [26417316](#).
72. Wetwitayaklung P, Limmatvapirat C, Phaeachamud T. Antioxidant and anticholinesterase activities in various parts of *Sonneratia caseolaris* (L.). *Indian J Pharm Sci*. 2013;75(6):649-56. PMID [24591739](#).
73. Barman A, Ahmed T, Das H, Biswas B, Ali M, Acharyya R. Evaluation of antidiabetic potential of extract of *Sonneratia caseolaris* (L.) engl leaves against alloxan-induced diabetes in mice. *TJNPR*. 2021;5(1):77-83. doi: [10.26538/tjnpr/v5i1.9](https://doi.org/10.26538/tjnpr/v5i1.9).
74. Munira MS, Islam MA, Islam MS, Koly SF, Nesa ML, Muhit MA. Phytochemical screening and comparative antioxidant activities of fractions isolated from *Sonneratia caseolaris* (Linn.) bark extracts. *Eur J Med Plants*. 2019;28(4):1-9. doi: [10.9734/ejmp/2019/v28i430141](https://doi.org/10.9734/ejmp/2019/v28i430141).
75. Bokshi B. Bioactivities of *Sonneratia caseolaris* (Linn.) leaf and stem using different solvent systems. *BJSTR*. 2020 Nov;31(5):24578-82. doi: [10.26717/BJSTR.2020.31.005175](https://doi.org/10.26717/BJSTR.2020.31.005175).
76. Bokshi B, Zilani MN, Malakar A, Roy DN, Shilpi JA, Sadhu SK. Study of analgesic and antidiarrhoeal activities of *Sonneratia caseolaris* (Linn.) leaf and stem using different solvent system. *Indonesian J Pharm*. 2013;24(4):253-8. doi: [10.14499/indonesianjpharm0iss0pp253-258](https://doi.org/10.14499/indonesianjpharm0iss0pp253-258).
77. Lakshmi V, Srivastava S, Mishra SK, Srivastava MN, Srivastava K, Puri SK. Antimalarial activity in *Xylocarpus granatum* (Koen). *Nat Prod Res*. 2012;26(11):1012-5. doi: [10.1080/14786419.2010.535000](https://doi.org/10.1080/14786419.2010.535000), PMID [21787243](#).
78. Ren JL, Zou XP, Li WS, Shen L, Wu J. Limonoids containing a C₁-o-C₂₉ moiety: isolation, structural modification and antiviral activity. *Drugs*. 2018;16(11):434. doi: [10.3390/md16110434](https://doi.org/10.3390/md16110434), PMID [30400349](#).
79. Simlai A, Roy A. Biological activities and chemical constituents of some mangrove species from sundarban estuary: an overview. *Pharmacogn Rev*. 2013;7(14):170-8. doi: [10.4103/0973-7847.120518](https://doi.org/10.4103/0973-7847.120518), PMID [24347925](#).
80. Misra S, Verma M, Mishra SK, Srivastava S, Lakshmi V, Misra Bhattacharya S. Gedunin and photogedunin of *Xylocarpus granatum* possess anti-filarial activity against human lymphatic filarial parasite brugia malayi in experimental rodent host. *Parasitol Res*. 2011;109(5):1351-60. doi: [10.1007/s00436-011-2380-x](https://doi.org/10.1007/s00436-011-2380-x), PMID [21523424](#).
81. Uddin SJ, Grice ID, Tiralongo E. Cytotoxic effects of Bangladeshi medicinal plant extracts. *Evid Based Complement Alternat Med*. 2011;2011:578092. doi: [10.1093/ecam/nep111](https://doi.org/10.1093/ecam/nep111), PMID [19706693](#).

82. Prihanto AA. Cytotoxic antioxidant and antibacterial activity of methanol extract of *Xylocarpus moluccensis* fruit husk. In: Proceeding of the international conference on basic science held at malang indonesia. Galaxy Science Publisher; 2011. p. 2-5.
83. Eldeen IM, Mohamed H, Tan WN, Siong JY, Andriani Y, Tengku Muh TS. Cyclooxygenase 5-lipoxygenase and acetylcholinesterase inhibitory effects of fractions containing α -guaiene and oil isolated from the root of *Xylocarpus moluccensis*. *Res J Med Plants.* 2016;10(4):286-94. doi: [10.3923/rjmp.2016.286.294](https://doi.org/10.3923/rjmp.2016.286.294).
84. Chaudhry GE, Sohimi NK, Mohamad H, Zafar MN, Ahmed A, Sung YY. *Xylocarpus moluccensis* induces cytotoxicity in human hepatocellular carcinoma HepG2 cell line via activation of the extrinsic pathway. *Asian Pac J Cancer Prev.* 2021;22 Suppl 1:17-24. doi: [10.31557/APJCP.2021.22.S1.17](https://doi.org/10.31557/APJCP.2021.22.S1.17), PMID 33576208.
85. Srivastava AK, Tiwari P, Srivastava SP, Srivastava R, Mishra A, Rahuja N. Antihyperglycaemic and antidiabetic activities in ethyl acetate fraction of fruits of marine mangrove *Xylocarpus moluccensis*. *Int J Pharm Pharm Sci.* 2014;6(1):809-26.
86. Muhtadi SA, Nurcahyanti W, Sutrisna EM. The potential of salam leaves (*syzigium polyanthum* walp.) and black cumin seed (*nigella sativa* linn) as candidate standarized herbal medicine of uric acid. *Pharmacon.* 2012;13(1):30-6.
87. Saroyo H, Saputri NF. Cytotoxicity of mangrove leaves (*rhizophora*) ethanolic extract on cancer cells. *J Nutraceuticals Herb Med.* 2021;4(1):43-52. doi: [10.23917/jnhm.v4i1.15657](https://doi.org/10.23917/jnhm.v4i1.15657).